SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-253090
Filing Date
2023-10-10
Accepted
2023-10-10 07:33:52
Documents
17
Period of Report
2023-10-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d558787d8k.htm   iXBRL 8-K 59242
2 EX-2.1 d558787dex21.htm EX-2.1 565135
3 EX-3.1 d558787dex31.htm EX-3.1 4868
4 EX-3.2 d558787dex32.htm EX-3.2 6231
5 EX-99.1 d558787dex991.htm EX-99.1 49522
6 EX-99.2 d558787dex992.htm EX-99.2 67882
  Complete submission text file 0001193125-23-253090.txt   1066502

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20231008.xsd EX-101.SCH 2836
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20231008_lab.xml EX-101.LAB 17981
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20231008_pre.xml EX-101.PRE 11249
11 EXTRACTED XBRL INSTANCE DOCUMENT d558787d8k_htm.xml XML 3405
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 231315658
SIC: 2834 Pharmaceutical Preparations